Companies hope to accelerate fight against cancer
GEDi Cube, an artificial intelligence (AI) company, and Renovaro Biosciences, a pre-clinical biotechnology organization, have revealed an exclusive letter of intent to merge into a single entity. As part of a potential merger, the focus would be on accelerating diagnosis, enhancing treatment effectiveness, discovering new therapies, and expanding access to life-saving technologies for cancer and other diseases.
"We are rapidly expanding our technologies to include other cancers and diseases," said Craig Rhodes, CEO, GEDi Cube, in a company press release. "I believe that uniting with Renovaro BioSciences’ potential solid tumor therapies is not merely synergistic. It could also create a multiplier effect to expedite diagnosis, improve treatment outcomes and discover, in silico, new therapies to improve many lives.”
Reference: AI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against Cancer. Business Wire. August 9, 2023. Accessed August 10, 2023. https://www.businesswire.com/news/home/20230809952021/en/AI-Company-GEDi-Cube-and-Renovaro-Biosciences-Announce-a-Binding-Exclusive-Letter-of-Intent-to-Merge-Accelerating-Fight-Against-Cancer
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Applying Porter’s Five Forces to Portfolio Management in Pharmaceutical R&D: A Strategic Roadmap
March 17th 2025The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic portfolio management to optimize resource allocation and enhance competitive advantage.